BioWorld. Link to homepage.
BioWorld
BioWorld Science
BioWorld Asia
Data Snapshots
Biopharma
Medical technology
Infographics: Dynamic digital data analysis
Index insights
NME Digest
Special reports
Infographics: Dynamic digital data analysis
Trump administration impacts
Med-tech outlook 2026
Under threat: mRNA vaccine research
BioWorld at 35
Biopharma M&A scorecard
Bioworld 2025 review
BioWorld MedTech 2025 review
BioWorld Science 2025 review
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Coronavirus
More reports can be found here
BioWorld. Link to homepage.
Sign In
Sign Out
My Account
Subscribe
BioWorld - Friday, March 27, 2026
Home
»
Newsletters
» BioWorld Science
BioWorld Science
March 29, 2019
View Archived Issues
Novel optimized allosteric SHP2 inhibitors that modulate MAPK signaling
Read More
Curl therapeutic RNA up into ball
Read More
The many shapes of tauopathy
Read More
Cathepsin S has a pathogenic role in CF and smoke-induced COPD: a potential target for lung diseases
Read More
Novel small-molecule RXFP3/4 agonist increases food intake in vivo
Read More
FT-113 shows promising antitumor activity in preclinical models
Read More
NLRP3 antagonist IFM-2427 enters first-in-human trial
Read More
Propellon Therapeutics discovers WDR5/MLL1 interaction inhibitors
Read More
New Toll-like receptor 7 agonists identified at BioNTech
Read More
Bioardis patents fibroblast growth factor receptor 4 inhibitors
Read More
Phase III PATENCY-2 trial of vonapanitase does not meet its coprimary endpoints
Read More
New ALK gene translocation found in gynecologic clear-cell carcinoma
Read More
Velicept presents positive topline results from VEL-2002 study of solabegron
Read More
Promising preclinical and first-in-human data presented for PRI-002
Read More
VALZ-pilot as the first clinical study to evaluate antiviral valaciclovir for the treatment of AD
Read More
NIAID initiates phase I study of inactivated subunit H5N1 influenza vaccine
Read More
Researchers identify new mutations in uveal melanoma
Read More
Phase II study of Foxy-5 as neoadjuvant therapy in Wnt-5a low colon cancer
Read More
Cimzia becomes the first and only FDA-approved treatment for nonradiographic axial spondyloarthritis
Read More
Odonate Therapeutics initiates CONTESSA TRIO phase II study of tesetaxel
Read More
Gilead Sciences and Galapagos present updated results for phase III studies of filgotinib
Read More
Pannexin 1 channelopathy causes human oocyte death
Read More
Orchard Therapeutics presents new registrational data for OTL-200 in MLD
Read More
First patient dosed in ReCLAIM-2 phase II study of elamipretide in AMD
Read More
Positive expression results presented from the casimersen arm of the ESSENCE study
Read More
